

Jeffrey B Washam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2553482/publications.pdf>

Version: 2024-02-01

27
papers

826
citations

758635

12
h-index

610482

24
g-index

28
all docs

28
docs citations

28
times ranked

1669
citing authors

#	ARTICLE	IF	CITATIONS
1	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2016, 133, 352-360.	1.6	141
2	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet, The</i> , 2015, 385, 2363-2370.	6.3	123
3	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <i>BMJ, The</i> , 2016, 353, i2868.	3.0	123
4	Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 47-55.	0.9	95
5	Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	66
6	Characteristics, Management, and Outcomes of Cocaine-Positive Patients With Acute Coronary Syndrome (from the National Cardiovascular Data Registry). <i>American Journal of Cardiology</i> , 2014, 113, 749-756.	0.7	38
7	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.	0.7	36
8	Identifying the Infarct-Related Artery in Patients With Non-“ST-Segment” Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007305.	1.4	32
9	Prevention of Critical Care Complications in the Coronary Intensive Care Unit: Protocols, Bundles, and Insights From Intensive Care Studies. <i>Canadian Journal of Cardiology</i> , 2017, 33, 101-109.	0.8	23
10	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	1.1	21
11	Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among Non-“ST-Segment” Elevation Myocardial Infarction Patients on Home Warfarin Therapy. <i>Circulation</i> , 2012, 125, 1414-1423.	1.6	17
12	Anticoagulants. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 503-515.	0.8	16
13	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1550-1563.	1.2	16
14	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 389-397.	1.1	14
15	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 345-352.	1.0	13
16	Risks and Benefits of Antiplatelet Therapy in Uremic Patients. <i>Advances in Chronic Kidney Disease</i> , 2008, 15, 370-377.	0.6	11
17	Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 285-298.	1.0	8
18	Cangrelor use prior to left ventricular assist device surgery: a case series. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 131-133.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 567-572.	2.3	7
20	Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005628.	1.4	7
21	Edoxaban and the need for outcomes-based NOAC dosing. <i>Lancet, The</i> , 2015, 385, 2232-2233.	6.3	5
22	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. <i>American Heart Journal</i> , 2020, 220, 145-154.	1.2	3
23	Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?. <i>Current Cardiology Reports</i> , 2018, 20, 105.	1.3	2
24	Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". <i>Circulation</i> , 2016, 134, e7-8.	1.6	1
25	Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 279-284.	1.0	0
26	Direct Thrombin Inhibition During Left-Sided Catheter Ablation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 491-493.	1.3	0
27	Abstract 16902: Efficacy and Safety of Rivaroxaban versus Warfarin in Patients Taking Non-dihydropyridine Calcium Channel Blockers: Results From the ROCKET AF Trial. <i>Circulation</i> , 2015, 132, .	1.6	0